Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting

Despite the recent success of CAR T cells targeting CD19 and CD22 in hematological malignancies, the production of CAR T cells still requires an extensive manufacturing process. The well-established NK-92 cell line provides a promising alternative to produce CAR-modified effector cells in a GMP-comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Grote, Stefan, Mittelstaet, Joerg, Baden, Caroline, Chan, Kenneth Chun-Ho, Seitz, Christian, Schlegel, Patrick, Kaiser, Andrew, Handgretinger, Rupert, Schleicher, Sabine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781805/
https://www.ncbi.nlm.nih.gov/pubmed/33457105
http://dx.doi.org/10.1080/2162402X.2020.1825177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781805/
https://www.ncbi.nlm.nih.gov/pubmed/33457105
http://dx.doi.org/10.1080/2162402X.2020.1825177

Ejemplares similares